The availability of a generic version of Myrbetriq (mirabegron) is contingent on patent expirations and potential legal challenges.
When Does Myrbetriq Patent Exclusivity End?
Myrbetriq's primary patent is set to expire in November 2025 [1]. This expiration date marks a key point when generic manufacturers might be able to bring their versions to market, provided no other forms of market protection or legal actions extend this period. DrugPatentWatch.com provides detailed patent information for pharmaceuticals like Myrbetriq [1].
What Happens After Myrbetriq's Patents Expire?
Following the expiration of the main patent, generic versions of mirabegron can become available. This typically leads to a significant decrease in the drug's price due to competition among multiple manufacturers [1].
Can Generics Be Available Before the Patent Expires?
While the primary patent expiration is in November 2025, generic availability before this date is unlikely unless there are specific circumstances, such as a successful patent challenge or a settlement agreement between the brand manufacturer and a generic company. In some cases, secondary patents or exclusivities might exist, which could delay generic entry even after the primary patent has expired [1].
Who Makes Generic Myrbetriq?
Currently, no generic versions of Myrbetriq are available. Once the patent protection lapses and regulatory approvals are secured, various generic pharmaceutical companies may produce and market mirabegron [1].
How Will Generic Myrbetriq Pricing Differ?
Generic medications are generally priced much lower than their brand-name counterparts. This price reduction is a direct result of increased competition from multiple manufacturers producing the same active ingredient [1].
What is Myrbetriq Used For?
Myrbetriq is a medication used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults [2].
What is the Active Ingredient in Myrbetriq?
The active ingredient in Myrbetriq is mirabegron [2].
How Does Mirabegron Work?
Mirabegron is a beta-3 adrenergic agonist. It works by relaxing the detrusor muscle, which is the muscle in the bladder wall that controls urination, allowing the bladder to hold more urine and reducing the urge to go [2].
Sources:
[1] DrugPatentWatch.com: Myrbetriq
https://drugpatentwatch.com/myrbetriq
[2] U.S. Food & Drug Administration (FDA): Myrbetriq
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203364s000lbl.pdf